Key Takeaways
- At today’s prices, $1,000 a month in dividends takes about 4,762 shares of Bristol Myers Squibb, about 3,530 shares of Merck or about 3,659 shares of Gilead Sciences.
- Bristol Myers Squibb’s check is the cheapest at about $292,100, while Gilead’s costs about $623,000.
- Gilead’s dividend is the best covered, at 30% of free cash flow, and Merck’s is the least covered, at 66%.
- Bristol Myers Squibb’s biggest test is an expected $1.5 billion to $2 billion drop in Eliquis revenue in 2027.
Big drug stocks are an obvious place for a retiree to look for dividend income, and three of the biggest just raised their 2026 outlooks. Bristol Myers Squibb (BMY), Merck (MRK) and Gilead Sciences (GILD) all reported third-quarter results on Oct. 29.
So let’s take a hypothetical retiree who wants $1,000 a month in dividends, or $12,000 a year, from just one of them. At today’s prices, that dividend check costs anywhere from about $292,100 to about $623,000:
| Stock | Yield | Shares needed | Cost | Income a month | Cash dividend payout ratio (TTM) |
|---|---|---|---|---|---|
| Bristol Myers Squibb | 4.1% | 4,762 | $292,149 | $1,000 | 55% |
| Merck | 2.4% | 3,530 | $506,096 | $1,000 | 66% |
| Gilead Sciences | 1.9% | 3,659 | $622,981 | $1,000 | 30% |
Source: TIKR and StockAnalysis, at today’s prices and each company’s current dividend rate. Payout ratios for the twelve months to Sept. 30, 2026.
6 safe dividend stocks paying retirees 6%+ yields
There are over 100 stocks paying 6%+ annual dividends today.
But after an extensive investment review leveraging TIKR’s proprietary data, we now believe only six of them are truly safe for retirees.
They’re all yours as part of our new investment report. Learn more about how to get access right here.
Bristol Myers Squibb’s check costs the least
Bristol Myers Squibb’s 4.1% yield gets you there with about 4,762 shares, or about $292,100. Its business is in the middle of a handoff. Third-quarter revenue rose 7% to $13.1 billion, as its Growth Portfolio climbed 12% to $7.7 billion and Eliquis grew 26% worldwide, while generics hit older drugs like Revlimid, which fell 47%.
Eliquis is the catch. It starts losing exclusivity in Europe in the fourth quarter, and management expects a $1.5 billion to $2 billion step-down in its revenue in 2027.
For now, the dividend is well-covered, taking 55% of free cash flow over the twelve months to Sept. 30, up from 39.3% in fiscal 2025. From fiscal 2020 to fiscal 2025, free cash flow ran between $12.0 billion and $15.2 billion a year, against dividends of $4.08 billion to $5.05 billion:

CFO David Elkins said on the third-quarter call that business development remains a priority, “while continuing to return cash to our shareholders through our commitment to the dividend.”
Merck’s check is the least covered
Merck’s 2.4% yield takes about 3,530 shares, or about $506,100, for the same $1,000 a month. Third-quarter sales rose 5% to $18.1 billion, led by Keytruda, up 6% to $8.6 billion, and Winrevair, up 93% to $694 million. Keytruda’s own loss of exclusivity is coming, but CFO Caroline Litchfield sees it as “really more of a hill on the overall revenues of our company as we will, in short order, then return to strong growth.”
Merck’s dividend took 66% of free cash flow over the twelve months to Sept. 30, about where fiscal 2025 ended. Its free cash flow swings a lot more than its dividend, and it fell short of dividends in fiscal 2017 and fiscal 2020:

The dividend per share still rose from $2.48 in fiscal 2020 to $3.28 in fiscal 2025. “We remain committed to the dividend with the goal of increasing it over time,” Litchfield said on the call.
Gilead’s check is the safest, and the priciest
Gilead’s 1.9% yield makes it the most expensive route: about 3,659 shares, or about $623,000. That money buys the fastest-growing business of the three right now. Third-quarter product sales rose 13% to $8.3 billion, with HIV up 18%, and Gilead raised its 2026 product sales guidance to $31.0 billion-$31.3 billion from $30.1 billion-$30.4 billion.
Dividends took just 30% of free cash flow over the twelve months to Sept. 30, down from 42.3% in fiscal 2025, and free cash flow topped the dividend every year from fiscal 2016 to fiscal 2025:

Two things hold it back. Its dividend grew just 3.0% a year from fiscal 2020 to fiscal 2025 ($2.72 to $3.16 a share). And Medicare’s negotiated price for Biktarvy, its biggest drug, takes effect Jan. 1, 2028. Gilead puts the hit at about $1.5 billion of Biktarvy revenue that year.
I’d take the cheapest check
For me, it’s Bristol Myers Squibb. Its check costs about $330,800 less than Gilead’s, its 55% coverage leaves plenty of room, and its dividend grew fastest of the three, 6.2% a year from fiscal 2020 to fiscal 2025. At that pace, those same shares would pay about $20,686 a year in year 10.
Merck’s 66% makes it the most at risk of a cut, though “most at risk” doesn’t mean risky. It has paid through years when free cash flow fell short, and it’s on track to buy back about $3 billion of stock this year, which I’d expect to go long before the dividend does. Still, Bristol Myers Squibb hands you a better-covered check for less money.
Gilead is the safest of the three, and a retiree who never wants to think about a cut has a good case for paying up. But that’s more than double the money for the same $1,000 a month, with the slowest recent dividend growth.
Of course, Bristol Myers Squibb’s real test comes in 2027, when the Eliquis step-down hits and the Growth Portfolio has to fill the hole. The next big clue is milvexian, which management expects to match Eliquis on stroke and beat it on bleeding. Its atrial fibrillation readout is due in the first quarter of 2027.
Forget Bristol Myers Squibb: 6 safe 6%+ dividend yields you can buy right now
Dividends can hold the key to enormous wealth. But only if you buy the right ones.
Picking the right high-yield dividend stock can be the difference between a dream retirement…and scraping by every month, waiting for the next Social Security check to clear.
We’ve identified six stocks yielding 6%+ that we believe every retiree should know about right now. (And Bristol Myers Squibb isn’t one of them.)
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!